Clinical ink Announces Strategic Investment from Ardan Equity and GI Partners to Accelerate Next Phase of Growth

Ardan and GI to bring deep, complementary domain expertise across life sciences and healthcare technology and partner with management to further accelerate Clinical ink's growth

WINSTON-SALEM, N.C., Oct. 19, 2026 /PRNewswire/ -- Clinical ink, a global clinical trial technology company, today announced investments from Ardan Equity ("Ardan"), a private equity firm specializing in healthcare technology, through Ardan Equity Fund I and from GI Partners ("GI"), a leading private investment firm that has partnered with the company since 2020, through GI Partners Fund VI. Existing investors, including GI Partners Fund V, realized a full exit of their prior investments, and Ardan and GI Partners both invested new equity in a co-control partnership.

Clinical ink provides electronic clinical outcome assessments (eCOA), connected device and other eClinical technologies to pharmaceutical companies and contract research organizations (CROs) to capture complex clinical trial data. Its combination of configurable technology, complex endpoint expertise, and integrated device capabilities support the latest FDA requirements in clinical trials as well as the emerging era of technology-enabled clinical care.

Drawing on their complementary life sciences and healthcare technology expertise, Ardan and GI will collaborate closely with management to continue to scale the Clinical ink platform globally, pursue opportunities across clinical research and care, and deliver innovative solutions that meet the rapidly evolving needs of the industry, while maintaining the highest standards of quality and compliance.

Since GI's initial investment in 2020, Clinical ink has expanded its global footprint, market position, platform, and capabilities. During that time, the company has meaningfully grown revenue, expanded therapeutic areas, deepened preferred provider relationships with leading pharmaceutical companies, launched differentiated solutions (including GlucoseReady and SPUR), and began its expansion into clinical care disease management through the Kaitality™ application.

Dave Kreter, Managing Director and Head of Healthcare at GI Partners, said, "We are pleased with the performance of the company since our 2020 investment and the tremendous progress the company has made in expanding its customer base and strengthening its position as a leading global clinical trial technology provider. Our partnership with CEO Jonathan Goldman and the Clinical ink team, together with GI's decade-plus experience investing in the healthcare technology and pharma services space, have delivered strong results to date. Looking ahead, we believe the accelerating pace of pharma R&D, the increasing complexity in clinical trials, and the need for high-quality tech solutions will provide strong tailwinds behind Clinical ink, and we look forward to building on that success alongside Ardan as the company enters its next phase of growth."

"We're delighted to welcome Clinical ink as our inaugural investment in Ardan Equity Fund I and as our eighth platform investment since 2020. We believe Clinical ink is at a key inflection point, with a compelling platform, a growing portfolio of leading pharmaceutical sponsors, and a strong path towards further expanding its footprint across the industry," said Noah Lewis, Managing Partner at Ardan Equity. "Its differentiated technology, endpoint expertise, and patient-centric approach make Clinical ink a compelling partnership for Ardan and an ideal fit for our investment thesis, our healthcare and life sciences technology sector specialist strategy, and our portfolio. We look forward to partnering with GI, Jonathan Goldman and the Clinical ink management team as we seek to accelerate the company's next phase of growth."

Jonathan Goldman, MD, Chief Executive Officer of Clinical ink, stated, "The management team and I are excited to work closely with Ardan and GI Partners to drive the next chapter of Clinical ink's evolution. We were impressed with Ardan's expertise, capabilities, and commitment to our company's growth. Our team is delighted that our long-term investors at GI remain with us given their longstanding experience with the company and its growth plans. The new investment by Ardan and GI represents a very positive development for our customers, the patients they serve, and the Clinical ink team."

Centerview Partners LLC and Guggenheim Securities, LLC served as financial advisors and Ropes & Gray LLP served as legal advisor to Clinical ink and GI Partners Fund V. Goodwin Procter LLP served as legal advisor to Ardan and Kirkland & Ellis LLP served as legal advisor to GI Partners Fund VI. Raymond James also acted as financial advisor to Ardan and GI Partners Fund VI. Ernst & Young, LLP acted as financial advisor to Ardan.

About Ardan Equity

Founded in 2019, Ardan Equity is a private equity firm exclusively focused on the healthcare and life sciences technology ecosystem. Ardan partners collaboratively with founders and management teams to accelerate growth and create differentiated platforms. As founders, operators, and investors, the Ardan team has built many of the defining healthcare and life sciences technology companies across life sciences, payer, provider and employer markets. Ardan utilizes its operator-investor approach and trusted network to help drive risk-adjusted performance. The firm invests capital on behalf of leading institutional investors globally and is headquartered in Palm Beach, Florida. For more information, please visit www.ardanequity.com.

About GI Partners

Founded in 2001, GI Partners is a private investment firm with over 180 employees and offices in San Francisco, New York, Dallas, Chicago, Greenwich, Scottsdale, and London. The firm has raised more than $50 billion and invests on behalf of leading institutional investors around the world through its private equity, real estate, and data infrastructure strategies. The private equity team invests primarily in companies in the healthcare, services, and software sectors. The real estate team focuses primarily on technology and healthcare properties as well as other specialized types of real estate. The data infrastructure team invests primarily in hard asset infrastructure businesses underpinning the digital economy. For more information, please visit www.gipartners.com.

About Clinical ink

Clinical ink is a global clinical technology company that helps pharmaceutical companies capture patient and clinical data through electronic clinical outcome assessments (eCOA) and connected device solutions in complex clinical trials. Its configurable technology platform combines deep endpoint expertise with integrated device capabilities to support increasingly sophisticated studies and generate regulatory-grade data. Clinical ink is headquartered in Winston-Salem, North Carolina with offices in Iowa, Pennsylvania and Copenhagen Denmark. For more information, please visit www.clinicalink.com.

Media Contacts
Ardan Equity
Urmi Jain, Investor Relations
[email protected]

GI Partners
Chris Tofalli, Public Relations
[email protected]

Emily Kuan, Investor Relations
[email protected]

SOURCE Clinical ink